Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage i cases

Modern Pathology

Volumn 24, Issue 5, 2011, Pages 653-664

  Yoshizawa, Akihiko ^a,b   Motoi, Noriko ^a,c   Riely, Gregory J ^a   Sima, Cami S ^a   Gerald, William L ^a   Kris, Mark G ^a   Park, Bernard J ^a   Rusch, Valerie W ^a   Travis, William D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

adenocarcinoma; adenocarcinoma in situ; bronchioloalveolar carcinoma; lung; micropapillary; minimally invasive adenocarcinoma; solid

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEW YORK; PNEUMONECTOMY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 79955571953     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.232     Document Type: Article

References (39)

1. Boyle P, Levin B. World Cancer Report 2008. International Agency for Research on Cancer: Lyon, 2008.
2. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO Mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32: 810-827.
5. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995;75:2844-2852.
6. Kim EA, Johkoh T, Lee KS, et al. Quantification of ground-glass opacity on high-resolution CT of small peripheral adenocarcinoma of the lung: pathologic and prognostic implications. AJR Am J Roentgenol 2001; 177:1417-1422. (Pubitemid 33081493)
7. Wu J, Ohta Y, Minato H, et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0cm or less in diameter. Ann Thorac Surg 2001;71:1772-1777. (Pubitemid 32554396)
8. Travis WD, Brambilla E, Noguchi M, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol 2011; 6:244-285.
9. Tsutsumida H, Nomoto M, Goto M, et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apopro-tein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 2007;20:638-647. (Pubitemid 46788870)
10. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003;27:101-109. (Pubitemid 36014903)
11. Amin MB, Tamboli P, Merchant SH, et al. Micropapil-lary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002;26:358-364. (Pubitemid 34184460)
12. Gaeta M, Blandino A, Pergolizzi S, et al. Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. Lung Cancer 2003;42: 319-326. (Pubitemid 37468545)
13. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchio-loalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996;179:254-259. (Pubitemid 26266402)
14. Yatabe Y, Koga T, Mitsudomi T, et al. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 2004;203:645-652. (Pubitemid 38714101)
15. Goldstein NS, Thomas M. Mucinous and nonmuci-nous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol 2001;116:319-325. (Pubitemid 32851962)
16. Garfield DH, Cadranel J. The importance of distinguishing mucinous and nonmucinous bronchioloal-veolar carcinomas. Lung 2009;187:207-208.
17. Lee HY, Lee KS, Han J, et al. Mucinous versus nonmucinous solitary pulmonary nodular bronchio-loalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer 2009;65: 170-175.
18. Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by bio-marker expression and in the response to gefitinib. Lung Cancer 2010;68:185-191.
19. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007;9:320-326. (Pubitemid 47305068)
20. Cohen PR, Yoshizawa A, Motoi N, et al. Signet ring cell features (SRCF) in lung adenocarcinoma: a cytologic feature or a histologic subtype? Mod Pathol 2010;23.
21. Deshpande CG, Yoshizawa A, Motoi N, et al. Clear cell change in lung adenocarcinoma: a cytologic change rather than a histologic variant. Mod Pathol 2009;22.
22. Goldstraw P. IASLC Staging Manual in Thoracic Oncology 1st edn. International Association for the Study of Lung Cancer, Editorial Rx Press: Orange Parka, FL, 2009.
23. Rusch VW, Appleman HD, Blackstone E, et al. Lung In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual 7th edn. American Joint Commision on Cancer, Springer: Chicago, 2009, pp 253-270.
24. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
25. Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol 2008; 3:1384-1390.
26. Travis WD, Brambilla E, Müller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart Vol 1 IARC: Lyon, 2004.
27. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
28. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010;116:659-669.
29. Riquet M, Foucault C, Berna P, et al. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg 2006;81:1988-1995. (Pubitemid 43775587)
30. Nagano T, Ishii G, Nagai K, et al. Structural and biological properties of a papillary component generating a micropapillary component in lung adenocarci-noma. Lung Cancer 2010;67:282-289.
31. Kamiya K, Hayashi Y, Douguchi J, et al. Histopatholo-gical features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 2008;21:992-1001.
32. Kawakami T, Nabeshima K, Makimoto Y, et al. Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors. Mod Pathol 2007;20:514-521. (Pubitemid 46631993)
33. Makimoto Y, Nabeshima K, Iwasaki H, et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (o/20mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology 2005;46:677-684. (Pubitemid 40834827)
34. Daly RC, Trastek VF, Pairolero PC, et al. Bronchoal-veolar carcinoma: factors affecting survival. Ann Thorac Surg 1991;51:368-376.
35. Manning Jr JT, Spjut HJ, Tschen JA. Bronchioloalveolar carcinoma: the significance of two histopathologic types. Cancer 1984;54:525-534. (Pubitemid 14087883)
36. Cadranel J, Quoix E, Baudrin L, et al. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronch-ioloalveolar carcinoma subtype. J Thorac Oncol 2009;4:1126-1135.
37. Garfield DH, Cadranel J, West HL. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer 2008;9:24-29. (Pubitemid 351251597)
38. Clayton F. Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer 1986;57:1555-1564. (Pubitemid 16135603)
39. Hayes DF, Allred C, Anderson BO, et al. Breast. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds), AJCC Cancer Staging Manual, 7th edn, Springer: New York, 2009.